Wei Qing, Niu Ting, Wang Mengyao, Yang Jinrong, Liu Pengpeng, Yi Yuyao
Department of Hematology and Research Laboratory of Hematology, West China Hospital, Sichuan University, Chengdu, China.
Acta Haematol. 2017;137(3):132-140. doi: 10.1159/000456645. Epub 2017 Mar 30.
To retrospectively validate the prognostic value of the latest Chinese disseminated intravascular coagulation (DIC) scoring system (CDSS) in hematological malignancies, 260 patients with confirmed hematological malignancies and suspected DIC in West China Hospital between 2011 and 2015 were included in this study. We evaluated via univariate and multivariate analyses the diagnostic biomarkers, and the cutoff levels used in the CDSS, except those for fibrinogen, were found to be valid. In subgroup analyses, the value of fibrinogen was found to be mainly unfit for the acute promyelocytic leukemia group. Forty-six patients (17.7%) had elevated fibrinogen levels (>4 g/L) and tended to have a poor prognosis, and thus we redetermined the cutoff value of fibrinogen (<1 g/L or >4 g/L was defined as abnormal). As a result, all of the markers used in the CDSS had prognostic value (including for the promyelocytic leukemia group); meanwhile, this modification also resulted in a larger area under the receiver operating characteristic curve compared to the CDSS and the International Society on Thrombosis and Haemostasis score. We believe that, with regard to prognosis prediction, this cutoff value modification for fibrinogen is preferable for DIC patients with a tendency toward severe hypofibrinogenemia. However, a multicenter, prospective study is needed to validate this possibility.
为回顾性验证最新的中国弥散性血管内凝血(DIC)评分系统(CDSS)在血液系统恶性肿瘤中的预后价值,本研究纳入了2011年至2015年期间在华西医院确诊为血液系统恶性肿瘤且疑似DIC的260例患者。我们通过单因素和多因素分析评估了诊断生物标志物,发现CDSS中使用的除纤维蛋白原外的临界值是有效的。在亚组分析中,发现纤维蛋白原的值主要不适用于急性早幼粒细胞白血病组。46例患者(17.7%)纤维蛋白原水平升高(>4 g/L)且预后往往较差,因此我们重新确定了纤维蛋白原的临界值(<1 g/L或>4 g/L定义为异常)。结果,CDSS中使用的所有标志物都具有预后价值(包括早幼粒细胞白血病组);同时,与CDSS和国际血栓与止血学会评分相比,这种修改还导致受试者工作特征曲线下面积更大。我们认为,对于预后预测,这种纤维蛋白原临界值的修改对于有严重纤维蛋白原血症倾向的DIC患者更可取。然而,需要进行多中心前瞻性研究来验证这种可能性。